March 27th 2024
During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Guideline Spotlights Early-Line Agents for GEP-NETs
November 29th 2023New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.
Read More
FDA Approves Pembrolizumab/Chemo for Gastric and GEJ Adenocarcinoma
November 16th 2023Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
Durvalumab/Bevacizumab Shows Clinically Meaningful PFS Improvement in HCC
November 9th 2023The phase 3 EMERALD-1 trial has met its primary end point and continues to assess durvalumab combined with transarterial chemoembolization and bevacizumab for the secondary end point of overall survival in patients with hepatocellular carcinoma.
Read More
Domvanalimab Regimen Shows Potential in First-Line GI Cancer Treatment
November 7th 2023Irrespective of PD-L1 expression, patients treated with domvanalimab, zimberelimab, and chemotherapy in arm A1 of the phase 2 EDGE-Gastric study demonstrated promising overall response rate and 6-month progression-free survival results.
Read More
SD-101 and Checkpoint Blockade Shows Early Favorable Outcomes in UMLM
November 6th 2023Encouraging progression-free survival and ctDNA molecular response rates were seen with SD-101 delivered via pressure-enabled drug delivery plus intravenous checkpoint inhibitors in patients with metastatic uveal melanoma with liver metastases.
Read More
Advancements in Immunotherapy and Novel Therapies for Colorectal Cancer
October 24th 2023Shared insight into the latest developments in immunotherapy and novel treatment options for colorectal cancer, including ongoing trials and the pursuit of new targets to enhance the immune response against cancer.
Watch
Personalized Care in CRC: Targeted Therapies and Multidisciplinary Collaboration
October 24th 2023Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, explore the forefront of colorectal cancer treatment, featuring targeted therapies, immunotherapy options, and the power of multidisciplinary teamwork.
Watch
Lenvatinib/Pembrolizumab Plus Chemotherapy Shows Manageable Toxicity in mESCC
October 23rd 2023The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.
Read More
KEYNOTE-811 Trial of Pembrolizumab Combo Improves PFS in HER2+ Gastric/GEJ Cancer
October 20th 2023The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.
Read More
Improved pCR in Gastric/GEJ Cancer with Durvalumab/Chemo
October 20th 2023The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.
Read More